Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

KRTX - Karuna Therapeutics, Inc.

Close
329.79
329.790   100.000%

Share volume: 0
Last Updated: Fri 15 Mar 2024 08:12:07 PM CET
Pharmaceutical Preparation Manufacturing : 2.72%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
34%
Profitability 25%
Dept financing 1%
Liquidity 75%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
3.99%
2 Year
71.83%
Key data
Stock price
$329.79
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
-$11.73
52 WEEK RANGE
$314.15 - $329.99
52 WEEK CHANGE
$4.21
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
38.199 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Steven M. Paul
Region: US
Website: karunatx.com
Employees: 210
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia.

Recent news